The role of S100A10 in cancer was first identified in acute promyelocytic leukemia (APL), a subtype characterized by the expression of a fusion protein formed by the fusion of retinoic acid receptor alpha with promyelocytic leukemia (PML-RARα) genes [61]. This evidence concerns the gene RARA and acute promyelocytic leukemia.